AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06488105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Counseling
Description: Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework
Study NCT06488105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Followup
Description: Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
Study NCT06488105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Followup
Description: Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
Study NCT06569303 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Incredible Years® School Age Basic Parent Training Program
Description: The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
Study NCT05869721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
Study NCT06149429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized virtual reality experience
Description: The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset.
Study NCT06552091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-hypnosis sessions
Description: 3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
Study NCT05727891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tonabersat
Description: Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Study NCT05727891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Study NCT04975880 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SC+ Hemodialysis System
Description: Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
Study NCT05592678 — intervention group
Intervention type: OTHER
Intervention: Donepezil
Description: Donepezil is administered as a standard of care treatment by the subject's provider.
Study NCT05461768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion
Study NCT05130450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.
Study NCT04636710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
Study NCT06191263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Study NCT06191263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
Study NCT04865081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACCIN box
Description: The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
Study NCT06195111 — intervention group
Intervention type: DRUG
Intervention: Trifluridine/Tipiracil
Description: This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
Study NCT06535737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib (Cabometyx) 60, 40 and 20 mg
Study NCT06569303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years® School Age Basic Parent Training Program
Description: The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
Study NCT06569303 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: American Academy of Pediatrics, Bright Futures Handouts
Description: Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
Study NCT05252754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsule
Description: Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
Study NCT05252754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO, 1-2 hours prior to endoscopy.
Study NCT05252754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rectal Indomethacin
Description: 100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
Study NCT05252754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal Indomethacin
Description: 100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
Study NCT05037097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-165
Description: Dose 3
Study NCT05037097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-154
Description: Dose 2
Study NCT05037097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021
Description: Dose 1
Study NCT05824208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRENAYOGA - prenatal yoga
Description: The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
Study NCT05963568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polycap
Description: Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.
Study NCT05224531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1 Administration
Description: CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 23.0°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 27.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 28.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35.5°C WBGT - Fixed Work Rate
Description: For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 26.0°C WBGT - Fixed work-to-rest ratio
Description: For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30.5°C WBGT - Fixed work-to-rest ratio
Description: For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production
Study NCT04767347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30.5°C WBGT - Fixed work-to-rest ratio (high intensity)
Description: For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production
Study NCT05058430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical salivary stimulator system assigned to subjects with xerostomia
Description: SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
Study NCT05058430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Electrical salivary stimulator system assigned to subjects without xerostomia
Description: SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
Study NCT05032807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard formulation
Description: Cannabidiol 1000mg standard formulation, single dose, oral
Study NCT05032807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel formulation
Description: Cannabidiol 1000mg with lipid matrix, single dose, oral
Study NCT05475340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
Study NCT05737771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DWC202213
Description: DWC202213
Study NCT05737771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1563
Description: DWJ1563
Study NCT03979664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activapatch intellidose 2.5 using active Iontophoresis
Description: Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
Study NCT03979664 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Activapatch intellidose 2.5 using inactive Iontophoresis
Description: Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
Study NCT03979664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
Study NCT05378542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application usage
Description: The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
Study NCT05387590 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Preventiometer device with wellness coaching
Description: Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
Study NCT05960955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: IV infusion,Specified dose on specified days
Study NCT05960955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days
Study NCT04938635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 60 mg QD
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
Study NCT05960955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion,Specified dose on specified days
Study NCT05960955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: Oral,Specified dose on specified days
Study NCT05960955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion,Specified dose on specified days
Study NCT04938635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 60 mg BID
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
Study NCT04938635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 120 mg BID
Description: Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
Study NCT04938635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
Study NCT05737771 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DWP16001
Description: DWP16001
Study NCT06567119 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SPOT-mRNA01
Description: SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs) ,single-dose subcutaneous injection
Study NCT06567119 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile isotonic solution, subcutaneous injection
Study NCT06298877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty and Quality of Life evaluation
Description: Frailty and Quality of Life evaluation after surgery
Study NCT05960955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV infusion,Specified dose on specified days
Study NCT04758000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI > 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified.
Study NCT04837677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT1419
Description: PRT1419 will be administered by intravenous infusion
Study NCT04508543 — intervention group
Intervention type: OTHER
Intervention: Non-verbal communication score
Description: 1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
Study NCT04847089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor imagery BCI training
Description: Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
Study NCT05673304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT anticipated boost
Description: 24 Gy in 3 fractions to the tumour
Study NCT06085625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Surgery Survey
Description: Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.